{"id":"NCT01802073","sponsor":"Stanford University","briefTitle":"Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects","officialTitle":"Treatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-01","primaryCompletion":"2015-08","completion":"2015-08","firstPosted":"2013-03-01","resultsPosted":"2018-09-21","lastUpdate":"2018-09-21"},"enrollment":34,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Sclerosing Cholangitis"],"interventions":[{"type":"DRUG","name":"Oral Vancomycin","otherNames":["Vancocin"]}],"arms":[{"label":"Oral Vancomycin","type":"EXPERIMENTAL"}],"summary":"Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis.","primaryOutcome":{"measure":"Count of Participants With Elevated Alanine Aminotransferase (ALT) at Baseline and With Clinically Significant Improvement at Month 3","timeFrame":"Baseline; Month 3","effectByArm":[{"arm":"Oral Vancomycin-Children","deltaMin":10,"sd":null},{"arm":"Oral Vancomycin-Adults","deltaMin":6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["23054338","32633158"],"seeAlso":["http://med.stanford.edu/clinicaltrials/"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":14},"commonTop":[]}}